Logo image of ACXP

ACURX PHARMACEUTICALS INC (ACXP) Stock Fundamental Analysis

NASDAQ:ACXP - US00510M1045 - Common Stock

4.36 USD
-0.26 (-5.63%)
Last: 9/2/2025, 4:51:25 PM
Fundamental Rating

1

Overall ACXP gets a fundamental rating of 1 out of 10. We evaluated ACXP against 542 industry peers in the Biotechnology industry. While ACXP seems to be doing ok healthwise, there are quite some concerns on its profitability. ACXP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ACXP had negative earnings in the past year.
In the past year ACXP has reported a negative cash flow from operations.
ACXP had negative earnings in each of the past 5 years.
ACXP had a negative operating cash flow in each of the past 5 years.
ACXP Yearly Net Income VS EBIT VS OCF VS FCFACXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

ACXP's Return On Assets of -162.38% is on the low side compared to the rest of the industry. ACXP is outperformed by 87.27% of its industry peers.
ACXP has a Return On Equity of -280.37%. This is in the lower half of the industry: ACXP underperforms 70.48% of its industry peers.
Industry RankSector Rank
ROA -162.38%
ROE -280.37%
ROIC N/A
ROA(3y)-227.85%
ROA(5y)-184.53%
ROE(3y)-923.45%
ROE(5y)-608.69%
ROIC(3y)N/A
ROIC(5y)N/A
ACXP Yearly ROA, ROE, ROICACXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACXP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACXP Yearly Profit, Operating, Gross MarginsACXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, ACXP has more shares outstanding
Compared to 5 years ago, ACXP has more shares outstanding
ACXP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACXP Yearly Shares OutstandingACXP Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K
ACXP Yearly Total Debt VS Total AssetsACXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -19.29, we must say that ACXP is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -19.29, ACXP is doing worse than 83.95% of the companies in the same industry.
There is no outstanding debt for ACXP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.29
ROIC/WACCN/A
WACCN/A
ACXP Yearly LT Debt VS Equity VS FCFACXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

ACXP has a Current Ratio of 2.38. This indicates that ACXP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.38, ACXP is doing worse than 70.48% of the companies in the same industry.
A Quick Ratio of 2.38 indicates that ACXP has no problem at all paying its short term obligations.
ACXP has a Quick ratio of 2.38. This is in the lower half of the industry: ACXP underperforms 67.90% of its industry peers.
Industry RankSector Rank
Current Ratio 2.38
Quick Ratio 2.38
ACXP Yearly Current Assets VS Current LiabilitesACXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ACXP have decreased strongly by -284.35% in the last year.
EPS 1Y (TTM)-284.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-626.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ACXP will show a very negative growth in Earnings Per Share. The EPS will decrease by -42.89% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1131.03%
EPS Next 2Y-235.66%
EPS Next 3Y-65.55%
EPS Next 5Y-42.89%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACXP Yearly Revenue VS EstimatesACXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2027 2028 2029 2030 2031 2032 50M 100M 150M
ACXP Yearly EPS VS EstimatesACXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACXP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACXP Price Earnings VS Forward Price EarningsACXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACXP Per share dataACXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

A cheap valuation may be justified as ACXP's earnings are expected to decrease with -65.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-235.66%
EPS Next 3Y-65.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACXP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACURX PHARMACEUTICALS INC

NASDAQ:ACXP (9/2/2025, 4:51:25 PM)

4.36

-0.26 (-5.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-11 2025-11-11
Inst Owners15.43%
Inst Owner Change-25.38%
Ins Owners10.95%
Ins Owner Change0%
Market Cap6.89M
Analysts82.22
Price Target62.93 (1343.35%)
Short Float %N/A
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.18%
Min EPS beat(2)18.25%
Max EPS beat(2)28.1%
EPS beat(4)4
Avg EPS beat(4)18.97%
Min EPS beat(4)12.85%
Max EPS beat(4)28.1%
EPS beat(8)5
Avg EPS beat(8)2.37%
EPS beat(12)7
Avg EPS beat(12)3.64%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)982.93%
PT rev (3m)1151.52%
EPS NQ rev (1m)-813.97%
EPS NQ rev (3m)-122.03%
EPS NY rev (1m)-2000%
EPS NY rev (3m)-1318.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-33.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.93
P/tB 1.93
EV/EBITDA N/A
EPS(TTM)-4.42
EYN/A
EPS(NY)-9.8
Fwd EYN/A
FCF(TTM)-5.17
FCFYN/A
OCF(TTM)-5.17
OCFYN/A
SpS0
BVpS2.26
TBVpS2.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -162.38%
ROE -280.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-227.85%
ROA(5y)-184.53%
ROE(3y)-923.45%
ROE(5y)-608.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.38
Quick Ratio 2.38
Altman-Z -19.29
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-284.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-626.92%
EPS Next Y-1131.03%
EPS Next 2Y-235.66%
EPS Next 3Y-65.55%
EPS Next 5Y-42.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y40.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.64%
EBIT Next 3Y3.95%
EBIT Next 5YN/A
FCF growth 1Y-13.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.68%
OCF growth 3YN/A
OCF growth 5YN/A